149 related articles for article (PubMed ID: 16515568)
1. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study.
Gaarenstroom KN; van der Hiel B; Tollenaar RA; Vink GR; Jansen FW; van Asperen CJ; Kenter GG
Int J Gynecol Cancer; 2006; 16 Suppl 1():54-9. PubMed ID: 16515568
[TBL] [Abstract][Full Text] [Related]
2. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
Olivier RI; Lubsen-Brandsma MA; Verhoef S; van Beurden M
Gynecol Oncol; 2006 Jan; 100(1):20-6. PubMed ID: 16188302
[TBL] [Abstract][Full Text] [Related]
3. [Screening pelvic tumours for hereditary risk of ovarian neoplasms, a cancer center experience].
Taïeb S; Rocourt N; Narducci F; Leblanc E; Adenis C; Fournier C; Doutrelant P; Peyrat JP; Vennin P
Bull Cancer; 2011 Feb; 98(2):113-9. PubMed ID: 21339094
[TBL] [Abstract][Full Text] [Related]
4. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.
Meeuwissen PA; Seynaeve C; Brekelmans CT; Meijers-Heijboer HJ; Klijn JG; Burger CW
Gynecol Oncol; 2005 May; 97(2):476-82. PubMed ID: 15863147
[TBL] [Abstract][Full Text] [Related]
5. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?
van der Velde NM; Mourits MJ; Arts HJ; de Vries J; Leegte BK; Dijkhuis G; Oosterwijk JC; de Bock GH
Int J Cancer; 2009 Feb; 124(4):919-23. PubMed ID: 19035463
[TBL] [Abstract][Full Text] [Related]
6. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study.
Tailor A; Bourne TH; Campbell S; Okokon E; Dew T; Collins WP
Ultrasound Obstet Gynecol; 2003 Apr; 21(4):378-85. PubMed ID: 12704748
[TBL] [Abstract][Full Text] [Related]
7. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
[TBL] [Abstract][Full Text] [Related]
9. Surveillance of women at high risk for hereditary ovarian cancer is inefficient.
Oei AL; Massuger LF; Bulten J; Ligtenberg MJ; Hoogerbrugge N; de Hullu JA
Br J Cancer; 2006 Mar; 94(6):814-9. PubMed ID: 16495917
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
11. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
12. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers.
Evans DG; Gaarenstroom KN; Stirling D; Shenton A; Maehle L; Dørum A; Steel M; Lalloo F; Apold J; Porteous ME; Vasen HF; van Asperen CJ; Moller P
J Med Genet; 2009 Sep; 46(9):593-7. PubMed ID: 18413372
[TBL] [Abstract][Full Text] [Related]
13. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.
Fishman DA; Cohen L; Blank SV; Shulman L; Singh D; Bozorgi K; Tamura R; Timor-Tritsch I; Schwartz PE
Am J Obstet Gynecol; 2005 Apr; 192(4):1214-21; discussion 1221-2. PubMed ID: 15846205
[TBL] [Abstract][Full Text] [Related]
14. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
Scheuer L; Kauff N; Robson M; Kelly B; Barakat R; Satagopan J; Ellis N; Hensley M; Boyd J; Borgen P; Norton L; Offit K
J Clin Oncol; 2002 Mar; 20(5):1260-8. PubMed ID: 11870168
[TBL] [Abstract][Full Text] [Related]
15. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study.
Cortesi L; De Matteis E; Toss A; Marchi I; Medici V; Contu G; Xholli A; Grandi G; Cagnacci A; Federico M
Oncology; 2017; 93(6):377-386. PubMed ID: 28848147
[TBL] [Abstract][Full Text] [Related]
17. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Casey MJ; Bewtra C
Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
[TBL] [Abstract][Full Text] [Related]
18. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.
Schwartz MD; Kaufman E; Peshkin BN; Isaacs C; Hughes C; DeMarco T; Finch C; Lerman C
J Clin Oncol; 2003 Nov; 21(21):4034-41. PubMed ID: 14581427
[TBL] [Abstract][Full Text] [Related]
19. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
Skates SJ; Greene MH; Buys SS; Mai PL; Brown P; Piedmonte M; Rodriguez G; Schorge JO; Sherman M; Daly MB; Rutherford T; Brewster WR; O'Malley DM; Partridge E; Boggess J; Drescher CW; Isaacs C; Berchuck A; Domchek S; Davidson SA; Edwards R; Elg SA; Wakeley K; Phillips KA; Armstrong D; Horowitz I; Fabian CJ; Walker J; Sluss PM; Welch W; Minasian L; Horick NK; Kasten CH; Nayfield S; Alberts D; Finkelstein DM; Lu KH
Clin Cancer Res; 2017 Jul; 23(14):3628-3637. PubMed ID: 28143870
[No Abstract] [Full Text] [Related]
20. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
Rosenthal AN; Fraser LSM; Philpott S; Manchanda R; Burnell M; Badman P; Hadwin R; Rizzuto I; Benjamin E; Singh N; Evans DG; Eccles DM; Ryan A; Liston R; Dawnay A; Ford J; Gunu R; Mackay J; Skates SJ; Menon U; Jacobs IJ;
J Clin Oncol; 2017 May; 35(13):1411-1420. PubMed ID: 28240969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
